Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1997 1
2003 3
2004 1
2006 3
2007 1
2008 5
2009 2
2010 3
2011 4
2012 6
2013 7
2014 3
2015 3
2016 8
2017 8
2018 8
2019 9
2020 5
2021 11
2022 9
2023 9
2024 2
2025 14
2026 4

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

121 results

Results by year

Filters applied: . Clear all
Page 1
VRK2 kinase pathogenic pathways in cancer and neurological diseases.
Lazo PA. Lazo PA. Biochim Biophys Acta Mol Cell Res. 2025 Jun;1872(5):119949. doi: 10.1016/j.bbamcr.2025.119949. Epub 2025 Apr 3. Biochim Biophys Acta Mol Cell Res. 2025. PMID: 40187568 Free article. Review.
Wild-type VRK2 is overexpressed in tumors and contributes to cancer development. In cells and tumors with low levels of nuclear VRK1, VRK2 generates by alternative splicing a shorter isoform (VRK2B) that lacks the C-terminal hydrophobic tail and permits its relocati …
Wild-type VRK2 is overexpressed in tumors and contributes to cancer development. In cells and tumors with low levels of nuclear VRK1, …
VRK2 targeting potentiates anti-PD-1 immunotherapy in hepatocellular carcinoma through MYC destabilization.
Su C, Liao Z, Mo J, Liu F, Wang W, Zhang H, Zhang H, Liu Y, Pan Y, Zhu H, Chen X, Zhang Z, Zhu P, Zhang B. Su C, et al. Nat Commun. 2025 Oct 10;16(1):9027. doi: 10.1038/s41467-025-64079-6. Nat Commun. 2025. PMID: 41073389 Free PMC article.
The stabilized MYC-VRK2 complex amplifies transcriptional activation of protumorigenic programs, including the immune checkpoint programmed cell death ligand 1 (PD-L1) and VRK2 itself, establishing a self-reinforcing oncogenic circuit. ...Our results reveal VRK2 …
The stabilized MYC-VRK2 complex amplifies transcriptional activation of protumorigenic programs, including the immune checkpoint prog …
VRK2, a Candidate Gene for Psychiatric and Neurological Disorders.
Li M, Yue W. Li M, et al. Mol Neuropsychiatry. 2018 Dec;4(3):119-133. doi: 10.1159/000493941. Epub 2018 Nov 7. Mol Neuropsychiatry. 2018. PMID: 30643786 Free PMC article. Review.
Here, we have reviewed the recent progress of genetic and molecular studies of VRK2, with an emphasis on its role in psychiatric illnesses and neurological functions. We believe that attention to this important gene is necessary, and further investigations of VRK2 m …
Here, we have reviewed the recent progress of genetic and molecular studies of VRK2, with an emphasis on its role in psychiatric illn …
VRK1 Is a Synthetic-Lethal Target in VRK2-Deficient Glioblastoma.
Shields JA, Meier SR, Bandi M, Mulkearns-Hubert EE, Hajdari N, Ferdinez MD, Engel JL, Silver DJ, Shen B, Zhang W, Hubert CG, Mitchell K, Shakya S, Zhao SC, Bejnood A, Zhang M, Tjin Tham Sjin R, Wilker E, Lathia JD, Andersen JN, Chen Y, Li F, Weber B, Huang A, Emmanuel N. Shields JA, et al. Cancer Res. 2022 Nov 2;82(21):4044-4057. doi: 10.1158/0008-5472.CAN-21-4443. Cancer Res. 2022. PMID: 36069976 Free PMC article.
Here, we demonstrate a paralog-based synthetic lethality by targeting vaccinia-related kinase 1 (VRK1) in glioblastoma (GBM) deficient of VRK2, which is silenced by promoter methylation in approximately two thirds of GBM. Genetic knockdown of VRK1 in VRK2-null or …
Here, we demonstrate a paralog-based synthetic lethality by targeting vaccinia-related kinase 1 (VRK1) in glioblastoma (GBM) deficient of …
VRK1 as a synthetic lethal target in VRK2 promoter-methylated cancers of the nervous system.
So J, Mabe NW, Englinger B, Chow KH, Moyer SM, Yerrum S, Trissal MC, Marques JG, Kwon JJ, Shim B, Pal S, Panditharatna E, Quinn T, Schaefer DA, Jeong D, Mayhew DL, Hwang J, Beroukhim R, Ligon KL, Stegmaier K, Filbin MG, Hahn WC. So J, et al. JCI Insight. 2022 Oct 10;7(19):e158755. doi: 10.1172/jci.insight.158755. JCI Insight. 2022. PMID: 36040810 Free PMC article.
VRK1 dependency was inversely correlated with expression of its paralog VRK2. VRK2 knockout sensitized cells to VRK1 loss, and conversely, VRK2 overexpression increased cell fitness in the setting of VRK1 loss. DNA methylation of the VRK2 promoter was …
VRK1 dependency was inversely correlated with expression of its paralog VRK2. VRK2 knockout sensitized cells to VRK1 loss, and …
Vrk2 deficiency elicits aggressive behavior in female zebrafish.
Umeda R, Teranishi H, Hada K, Shimizu N, Shiraishi H, Urushibata H, Lai S, Shide M, Carrasco Apolinario ME, Higa R, Shikano K, Shin T, Mimata H, Hikida T, Hanada T, Hanada R. Umeda R, et al. Genes Cells. 2022 Apr;27(4):254-265. doi: 10.1111/gtc.12924. Epub 2022 Feb 15. Genes Cells. 2022. PMID: 35094457 Free article.
VRK2 is also expressed in the brain; however, its molecular function in the central nervous system is mostly unknown. ...However, the pathophysiological relationship between VRK2 and neuropsychiatric disorders has not been fully investigated. In this study, we evalu …
VRK2 is also expressed in the brain; however, its molecular function in the central nervous system is mostly unknown. ...However, the …
VRK2 activates TNFalpha/NF-kappaB signaling by phosphorylating IKKbeta in pancreatic cancer.
Chen J, Qiao K, Zhang C, Zhou X, Du Q, Deng Y, Cao L. Chen J, et al. Int J Biol Sci. 2022 Jan 9;18(3):1288-1302. doi: 10.7150/ijbs.66313. eCollection 2022. Int J Biol Sci. 2022. PMID: 35173553 Free PMC article.
In this study, the regulation of TNFalpha/NF-kappaB signaling by VRK2 (vaccinia-related kinase 2) was investigated. The levels of VRK2 protein were examined by immunohistochemistry (IHC). ...An IKKbeta inhibitors abolished the promotive effect of VRK2 on the …
In this study, the regulation of TNFalpha/NF-kappaB signaling by VRK2 (vaccinia-related kinase 2) was investigated. The levels of …
VRK2 promotes colorectal cancer growth and impedes immunotherapy and 5-FU treatment efficacy.
Wu YT, Gao M, Cheng KY, Li L, Wang BQ, He YN, Zhang Y, Liu XY, Du RL, Li GQ, Liang YX, Zhang JF, Zhang XD, Liu Y. Wu YT, et al. Biochim Biophys Acta Mol Basis Dis. 2025 Apr;1871(4):167729. doi: 10.1016/j.bbadis.2025.167729. Epub 2025 Feb 18. Biochim Biophys Acta Mol Basis Dis. 2025. PMID: 39978443
Vaccinia-Related Kinase 2 (VRK2), a member of the vaccinia virus-related protein kinase family, is crucial in regulating apoptosis and tumor cell growth signaling pathways. ...These findings underscore VRK2's multifaceted role in promoting colorectal cancer developm …
Vaccinia-Related Kinase 2 (VRK2), a member of the vaccinia virus-related protein kinase family, is crucial in regulating apoptosis an …
VRK2 inhibition synergizes with PD-1 blockade to improve T cell responses.
Peled M, Tocheva AS, Adam K, Mor A. Peled M, et al. Immunol Lett. 2021 May;233:42-47. doi: 10.1016/j.imlet.2021.03.007. Epub 2021 Mar 16. Immunol Lett. 2021. PMID: 33741379 Free PMC article.
Moving into in vivo syngeneic tumor models, pharmacologic inhibition of VRK2 in combination with PD-1 blockade enhanced tumor clearance through T cell activation. This study suggests that VRK2 is a unique therapeutic target and that combination of VRK2 inhibi …
Moving into in vivo syngeneic tumor models, pharmacologic inhibition of VRK2 in combination with PD-1 blockade enhanced tumor clearan …
Elevated FBXL6 expression in hepatocytes activates VRK2-transketolase-ROS-mTOR-mediated immune evasion and liver cancer metastasis in mice.
Zhang J, Lin XT, Yu HQ, Fang L, Wu D, Luo YD, Zhang YJ, Xie CM. Zhang J, et al. Exp Mol Med. 2023 Oct;55(10):2162-2176. doi: 10.1038/s12276-023-01060-7. Epub 2023 Sep 1. Exp Mol Med. 2023. PMID: 37653031 Free PMC article.
Activated TKT further increased PD-L1 and VRK2 expression via the ROS-mTOR axis, leading to immune evasion and HCC metastasis. Targeting or knockdown of TKT significantly blocked FBXL6-driven immune evasion and HCC metastasis in vitro and in vivo. Notably, the level of act …
Activated TKT further increased PD-L1 and VRK2 expression via the ROS-mTOR axis, leading to immune evasion and HCC metastasis. Target …
121 results